IBRUTINIB [IMBRUVICA] - IBRUTINIB 140MG |

MILLIONHEALTHPHARMA

IBRUTINIB 140MG

DESCRIPTION

Imbruvica 140mg is a targeted drug aim to destroy the type of cell which has converted into
cancerous orends signals which make cancerous cells develop or multiply. In lymphoma, the
type of cell which becomes cancerous is called a ‘lymphocyte’ (a type of white blood cell that
fights infection). There are different types of lymphocyte which can become cancerous.
Imbruvica 140mg capsules attacks B lymphocytes (B cells) and is therefore necessary to treat B-
cell lymphomas.

Imbruvica 140mg

INDICATION

Imbruvica 140mg is an antineoplastic drug which is:

• Indicated for the treatment of Chronic lymphocytic leukaemia or small lymphocytic lymphoma
• Indicated for the treatment of Mantle cell lymphoma
• Indicated for the treatment of Waldenström Macroglobulinemia
• Indicated for the treatment of Marginal Zone lymphoma
• Indicated for the treatment of Graft vs Host Disease

MECHANISM OF ACTION

Ibrutinib prohibits the Bruton's tyrosine kinase (BTK)function. BTK is a basic signaling
molecule of the B-cell receptor signaling complex which plays an important role in the
endurance of malignant B cells.
Ibrutinib stops signals whichprompt malignant B cells to develop and multiply uncontrollably.
 Imbruvica 140mg
ADME

Absorption:
Time to peak plasma concentration of Imbruvica 140mg is 1-2 hours and drug taking with food
will increases ibrutinib exposure.
Distribution:
Human plasma protein level is 97.3% and Vd is 10,000L
Metabolism:
Metabolized to several metabolites mainly by cytochrome P450 CYP3A, and to a minor extent
by CYP2D6
Elimination:
Imbruvica 140mg was excretion via feces 80% and urine 10 %
Half-life of Imbruvica 140mg is 4-6 hours

DOSAGE MANAGEMENT

Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma :

The usual dose of imbruvica 140mg is 420mg given three 140mg capsules per oral qDay
While in concomitant use with bendamustine and rituximab the prescribed dose is 420mg PO
qDay administrated q28d for up to 6 cycles until progression or undesirable toxicity
Mantle Cell Lymphoma :
The usualdose of imbruvica 140mg is 560mg given four 140mg-mg capsules PO qDay.
Extend until disease progression or undesirable toxicity
Waldenström Macroglobulinemia :
The usualdose of imbruvica is 420mg given three 140mg capsules per oral qDay
When concomitant use with rituximab is 420 mg PO qDay plus rituximab administered weekly
for 4 consecutive weeks (weeks 1-4) continued by a second course of weekly rituximab for 4
consecutive weeks (weeks 17-20)
Marginal Zone Lymphoma :
The usualdose of imbruvica is 560mg given four 140mg-mg capsules PO qDay.
Extend until disease progression or undesirable toxicity
Graft vs Host Disease :
The usualdose of imbruvica is 420mg given three 140mg capsules per oral qDay
Extenduntil cGVHD development, relapsed of an underlying malignancy, or undesirable toxicity
occurs

Imbruvica 140mg

PRECAUTIONS

• While on treatment with Imbruvica 140mg capsules Hypertension occurs with a median
time to onset of 4.6 months; regulate for new onset hypertension or hypertension that is
not enough controlled after starting ibrutinib
• While on treatment with Imbruvica 140mg, Tumor lysis syndrome intermittently
resulted; assess the baseline risk (e.g., high tumor burden) and take suitable precautions
• While on treatment with Imbruvica Other malignancies (5-14%) resulted contains
carcinomas (1-3%); the most frequent second primary malignancy was nonmelanoma
skin cancer (4-11%)
• When administered to a pregnant woman,based on findings in animals, can cause fetal
risk
• While on treatment with Imbruvica 140mg, lethal and severe cases of renal failure
reported.
 Imbruvica 140mg

SIDE EFFECTS

More common side effects of Imbruvica 140mg :

Fever, Stomatitis, Dizziness, Urinary Tract Infection, Pneumonia, Dyspepsia, Petechiae,
Arthralgia, Nosebleeds, Skin infections, Asthenia, Muscle spasms, Shortness of breath,
Constipation, Rash, Sinusitis, Headache, Dehydration, Abdominal pain, Vomiting, Decreased
appetite, Cough.
More common side effects of Imbruvica 140mg :
Reduced neutrophils, Decreased haemoglobin, Fatigue, Bruising, Thrombocytopenia,
Musculoskeletal pain, Swelling, Upper respiratory tract infection, Nausea, Diarrhea.

Imbruvica 140mg

PREGNANCY

Pregnancy category is D;
While on treatment Imbruvica 140mg avoid becoming pregnancy and for up to 1 month after
ending treatment.

LACTATION
Avoid breast feeding during treatment with Imbruvica 140mg

STORAGE

Store the drug at 20°C- 25°C.

MISSED DOSE

If missed dose occurs, have it immediately before next dose time reaches or missed dose should
be avoid and follow the regular dosing schedule.
Must consult with doctor and follow the instructions given by them

CONTACT US

MAIL ID : millionhealthpharmaceuticals@gmail.com
PHONE NO : +91-9940472902
WEBSITE : https://millionpharma.com/ibrutinib-140mg.php